Analysis of metabolic response (MR) by positron emission tomography (PET) compared with tumor response by computed tomography (CT) from MPACT, a phase III trial comparing nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone for patients (pts) with metastatic adenocarcinoma of the pancreas

被引：0
|
作者：
Ramanathan, Ramesh K.
Von Hoff, Daniel D.
Moore, Malcolm J.
Teixeira, Luis
Siena, Salvatore
Tabernero, Josep
Goldstein, David
Wei, Xinyu
Lu, Brian
机构：
[1] Virginia G Piper Canc Ctr, Translat Genom Res Inst, Scottsdale, AZ USA
[2] Scottsdale Healthcare TGen, Virginia G Piper Canc Ctr Clin Trials, Scottsdale, AZ USA
[3] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada
[4] Hop St Antoine, F-75571 Paris, France
[5] Osped Niguarda Ca Granda, Falck Div Med Oncol, Milan, Italy
[6] Vall dHebron Univ Hosp, Barcelona, Spain
[7] Prince Wales Hosp, Sydney, NSW, Australia
[8] Celgene Corp, Summit, NJ USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 03期
关键词：
D O I：
10.1200/jco.2014.32.3_suppl.254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
254
引用
收藏
页数：1
相关论文
共 42 条
  • [1] Positron emission tomography (PET) response from a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients (pts) with metastatic adenocarcinoma of the pancreas
    Ramanathan, R. K.
    Von Hoff, D. D.
    Moore, M.
    Teixeira, L.
    Siena, S.
    Tabernero, J.
    Goldstein, D.
    Wei, X.
    Lu, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S611 - S611
  • [2] Dose delivery in a phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas
    Scheithauer, W.
    Von Hoff, D. D.
    Ramanathan, R. K.
    Moore, M.
    Tabernero, J.
    Goldstein, D.
    Hammel, P.
    Kunzmann, V.
    Ko, A.
    Romano, A.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S614 - S614
  • [3] Positron emission tomography response evaluation from a randomized phase III trial of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients with metastatic adenocarcinoma of the pancreas
    Ramanathan, R. K.
    Goldstein, D.
    Korn, R. L.
    Arena, F.
    Moore, M.
    Siena, S.
    Teixeira, L.
    Tabernero, J.
    Van Laethem, J. -L.
    Liu, H.
    McGovern, D.
    Lu, B.
    Von Hoff, D. D.
    ANNALS OF ONCOLOGY, 2016, 27 (04) : 648 - 653
  • [4] Evaluation of peripheral neuropathy in a phase Ill trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) vs G alone for patients with metastatic adenocarcinoma of the pancreas
    Goldstein, D.
    Von Hoff, D. D.
    Moore, M.
    Greeno, E.
    Ritch, P.
    Tortora, G.
    Ramanathan, R. K.
    Tabernero, J.
    Ko, A.
    Lu, B.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S613 - S613
  • [5] Updated survival from a randomized phase III trial (MPACT) of nab-paclitaxel plus gemcitabine versus gemcitabine alone for patients (pts) with metastatic adenocarcinoma of the pancreas
    Goldstein, David
    El Maraghi, Robert Hassan
    Hammel, Pascal
    Heinemann, Volker
    Kunzmann, Volker
    Sastre, Javier
    Scheithauer, Werner
    Siena, Salvatore
    Tabernero, Josep
    Teixeira, Luis
    Tortora, Giampaolo
    Van Laethem, Jean-Luc
    Young, Rosemary
    Wei, Xinyu
    Lu, Brian
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [6] Phase III study of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone in patients (pts) with metastatic pancreatic adenocarcinoma (mPC): Subgroup analysis of Canadian pts from the MPACT trial
    Tehfe, Mustapha Ali
    Dowden, Scot D.
    Kennecke, Hagen F.
    El-Maraghi, Robert Hassan
    Lesperance, Bernard
    Couture, Felix
    Letourneau, Richard
    Penenberg, Darryl Neil
    Romano, Alfredo
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [7] Prognostic factors (PFs) of survival in a randomized phase III trial (MPACT) of weekly nab-paclitaxel (nab-P) plus gemcitabine (G) versus G alone in patients (pts) with metastatic pancreatic cancer (MPC).
    Moore, Malcolm J.
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Hon, Jeremy K.
    Biakhov, Mikhail Yu
    Hingorani, Sunil R.
    Ganju, Vinod
    Weekes, Colin D.
    Scheithauer, Werner
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Goldstein, David
    Wei, Xinyu
    Romano, Alfredo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [8] Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT)
    Von Hoff, Daniel D.
    Ervin, Thomas J.
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey R.
    Moore, Malcolm J.
    Seay, Thomas E.
    Tjulandin, Sergei
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Van Cutsem, Eric
    Goldstein, David
    Wei, Xinyu
    Iglesias, Jose Luis
    Renschler, Markus Frederic
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04)
  • [9] Reduction in primary pancreatic and metastatic tumor burden in the phase III MPACT trial of nab-paclitaxel (nab-P) plus gemcitabine (Gem) versus Gem alone.
    Kunzmann, Volker
    Ramanathan, Ramesh K.
    Goldstein, David
    Penenberg, Darryl Neil
    Ferrara, Stefano
    Lu, Brian D.
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [10] Outcomes from the Asian region of the phase III APACT trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) alone for patients (pts) with resected pancreatic cancer (PC)
    Park, J. Oh
    Li, C-P.
    Chang, H-M.
    Shan, Y. S.
    Bendell, J.
    Garlipp, B.
    Hatoum, H.
    Laquente Saez, B.
    Salminen, T.
    Oettle, H.
    Kocsis, J.
    Lopez, R.
    Dowden, S.
    Karthaus, M.
    Lu, B.
    McGovern, D.
    Banerjee, S.
    Tempero, M.
    Oh, D-Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S1313 - S1313
12345